Exploring the chemical space of γ-secretase modulators

Trends in Pharmacological Sciences

Volumn 31, Issue 9, 2010, Pages 402-410

  Zettl, Heiko ^a   Weggen, Sascha ^b   Schneider, Petra ^a   Schneider, Gisbert ^a  

^a ETH ZURICH   (Switzerland)

^b HEINRICH HEINE UNIVERSITY   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

AMINE OXIDASE (FLAVIN CONTAINING) ISOENZYME A; AMYLOID BETA PROTEIN[1-42]; AMYLOID PRECURSOR PROTEIN; ARACHIDONATE 5 LIPOXYGENASE; CARPROFEN; FLURBIPROFEN; GAMMA SECRETASE; GAMMA SECRETASE INHIBITOR; GLUTAMATE RECEPTOR 1; GLUTAMATE RECEPTOR 2; INDOMETACIN; NONSTEROID ANTIINFLAMMATORY AGENT; NOTCH RECEPTOR; PROSTAGLANDIN SYNTHASE; SEROTONIN 3 RECEPTOR; SEROTONIN RECEPTOR; SIGNAL PEPTIDE; SULINDAC SULFIDE; TARENFLURBIL;

ACIDITY; ALZHEIMER DISEASE; ARTICLE; CLINICAL TRIAL; COMPUTER PROGRAM; DRUG MECHANISM; DRUG POTENCY; DRUG SAFETY; DRUG SCREENING; DRUG STRUCTURE; DRUG TARGETING; ENZYME INHIBITION; HUMAN; LIPOPHILICITY; NONHUMAN; PATHOPHYSIOLOGY; PHARMACOPHORE; PRIORITY JOURNAL; PROTEIN SYNTHESIS; PROTEIN SYNTHESIS INHIBITION; PROTON NUCLEAR MAGNETIC RESONANCE;

AMYLOID PRECURSOR PROTEIN SECRETASES; COMPUTER-AIDED DESIGN; DRUG DESIGN; DRUG EVALUATION, PRECLINICAL; ENZYME INHIBITORS; MODELS, BIOLOGICAL; MOLECULAR STRUCTURE; NONLINEAR DYNAMICS;

EID: 77956187227     PISSN: 01656147     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.tips.2010.05.007     Document Type: Article

References (58)

1. Wancata J., et al. Number of dementia sufferers in Europe between the years 2000 and 2050. Eur. Psychiatry 2003, 18:306-313.
2. Golde T.E. Alzheimer disease therapy: Can the amyloid cascade be halted?. J. Clin. Invest. 2003, 111:11-18.
3. Bergmans B.A., De Strooper B. Gamma-secretases: from cell biology to therapeutic strategies. Lancet Neurol. 2010, 9:215-226.
4. Steiner H., et al. Intramembrane proteolysis by gamma-secretase. J. Biol. Chem. 2008, 283:29627-29631.
5. Walsh D.M., Selkoe D.J. A beta oligomers - a decade of discovery. J. Neurochem. 2007, 101:1172-1184.
6. Kreft A.F., et al. Recent advances in the identification of gamma-secretase inhibitors to clinically test the Abeta oligomer hypothesis of Alzheimer's disease. J. Med. Chem. 2009, 52:6169-6188.
7. Harrison T., et al. Gamma-secretase as a target for drug intervention in Alzheimer's disease. Curr. Opin. Drug. Discov. Devel. 2004, 7:709-719.
8. Tomita T. Secretase inhibitors and modulators for Alzheimer's disease treatment. Expert Rev. Neurother. 2009, 9:661-679.
9. Leuchtenberger S., et al. Selective modulation of Abeta42 production in Alzheimer's disease: non-steroidal anti-inflammatory drugs and beyond. Curr. Pharm. Des. 2006, 12:4337-4355.
10. Takahashi Y., et al. Sulindac sulfide is a noncompetitive gamma-secretase inhibitor that preferentially reduces Abeta 42 generation. J. Biol. Chem. 2003, 278:18664-18670.
11. Weggen S., et al. A subset of NSAIDs lower amyloidogenic Abeta42 independently of cyclooxygenase activity. Nature 2001, 414:212-216.
12. Weggen S., et al. Abeta42-lowering nonsteroidal anti-inflammatory drugs preserve intramembrane cleavage of the amyloid precursor protein (APP) and ErbB-4 receptor and signaling through the APP intracellular domain. J. Biol. Chem. 2003, 278:30748-30754.
13. Warner T.D., Mitchell J.A. Cyclooxygenases: new forms, new inhibitors, and lessons from the clinic. FASEB J. 2004, 18:790-804.
14. Weggen S., et al. NSAIDs: small molecules for prevention of Alzheimer's disease or precursors for future drug development?. Trends Pharmacol. Sci. 2007, 28:536-543.
15. Kukar T., et al. Diverse compounds mimic Alzheimer disease-causing mutations by augmenting Abeta42 production. Nat. Med. 2005, 11:545-550.
16. Sahagan B.G., et al. Killing pain, not neurons. Nat. Med. 2005, 11:817-818.
17. Schmuker M., Schneider G. Processing and classification of chemical data inspired by insect olfaction. Proc. Natl. Acad. Sci. U. S. A. 2007, 104:20285-20289.
18. Schneider G., et al. Self-organizing molecular fingerprints: a ligand-based view on drug-like chemical space and off-target prediction. Future Med. Chem. 2009, 1:213-218.
19. Schneider P., et al. Self-organizing maps in drug discovery: compound library design, scaffold-hopping, repurposing. Curr. Med. Chem. 2009, 16:258-266.
20. Peretto I., La Porta E. Gamma-secretase modulation and its promise for Alzheimer's disease: a medicinal chemistry perspective. Curr. Top. Med. Chem. 2008, 8:38-46.
21. Eriksen J.L., et al. NSAIDs and enantiomers of flurbiprofen target gamma-secretase and lower Abeta 42 in vivo. J. Clin. Invest. 2003, 112:440-449.
22. Morihara T., et al. Selective inhibition of Abeta42 production by NSAID R-enantiomers. J. Neurochem. 2002, 83:1009-1012.
23. Green R.C., et al. Effect of tarenflurbil on cognitive decline and activities of daily living in patients with mild Alzheimer disease: a randomized controlled trial. J. Am. Med. Assoc. 2009, 302:2557-2564.
24. Galasko D.R., et al. Safety, tolerability, pharmacokinetics, and Abeta levels after short-term administration of R-flurbiprofen in healthy elderly individuals. Alzheimer Dis. Assoc. Disord. 2007, 21:292-299.
25. Frisoni G.B., et al. The clinical use of structural MRI in Alzheimer disease. Nat. Rev. Neurol. 2010, 6:67-77.
26. Craig-Schapiro R., et al. Biomarkers of Alzheimer's disease. Neurobiol. Dis. 2009, 35:128-140.
27. Narlawar R., et al. Scaffold of the cyclooxygenase-2 (COX-2) inhibitor carprofen provides Alzheimer gamma-secretase modulators. J. Med. Chem. 2006, 49:7588-7591.
28. Peretto I., et al. Synthesis and biological activity of flurbiprofen analogues as selective inhibitors of beta-amyloid1-42 secretion. J. Med. Chem. 2005, 48:5705-5720.
29. Wilson, F. et al. Cellzome AG. (Biphenyl)carboxylic acids and derivatives thereof, WO 2006045554.
30. Hall A., et al. Piperidine-derived gamma-secretase modulators. Bioorg. Med. Chem. Lett. 2010, 20:1306-1311.
31. Stanton M.G., et al. Fluorinated piperidine acetic acids as gamma-secretase modulators. Bioorg. Med. Chem. Lett. 2010, 20:755-758.
32. Page R.M., et al. Generation of Abeta38 and Abeta42 is independently and differentially affected by familial Alzheimer disease-associated presenilin mutations and gamma-secretase modulation. J. Biol. Chem. 2008, 283:677-683.
33. Rivkin A., et al. Piperazinyl pyrimidine derivatives as potent gamma-secretase modulators. Bioorg. Med. Chem. Lett. 2010, 20:1269-1271.
34. Rivkin A., et al. Purine derivatives as potent gamma-secretase modulators. Bioorg. Med. Chem. Lett. 2010, 20:2279-2282.
35. Kimura, T. et al. Eisai Co., Ltd. Cinnamide Compound, WO 2005115990.
36. Schneider G., et al. Voyages to the (un)known: adaptive design of bioactive compounds. Trends Biotechnol. 2009, 27:18-26.
37. Noeske T., et al. Predicting compound selectivity by self-organizing maps: cross-activities of metabotropic glutamate receptor antagonists. ChemMedChem 2006, 1:1066-1068.
38. Steri R., et al. Target profile prediction: cross-activation of peroxisome proliferator-activated receptor (PPAR) and farnesoid X receptor (FXR). Mol. Inform. 2010, 29:287-292.
39. Mestres J., Gregori-Puigjane E. Conciliating binding efficiency and polypharmacology. Trends Pharmacol. Sci. 2009, 30:470-474.
40. Kohonen T. Self-Organization and Associative Memory 1984, Springer-Verlag.
41. Zupan J., Gasteiger J. Neural Networks in Chemistry and Drug Design 1999, Wiley-VCH.
42. Schneider G., et al. 'Scaffold-hopping' by topological pharmacophore search: a contribution to virtual screening. Angew. Chem. Int. Ed. Engl. 1999, 38:2894-2896.
43. Schneider G., Baringhaus K.-H. Molecular Design: Concepts and Applications 2008, Wiley-VCH.
44. Schneider G., So S.-S. Adaptive Systems in Drug Design 2003, Landes Bioscience.
45. Li Y.M., et al. Photoactivated gamma-secretase inhibitors directed to the active site covalently label presenilin 1. Nature 2000, 405:689-694.
46. Morohashi Y., et al. Carboxyl-terminal fragment of presenilin is the molecular target of a dipeptidic gamma -secretase-specific inhibitor DAPT. J. Biol. Chem. 2006, 281:14670-14676.
47. Beher D., et al. Selected non-steroidal anti-inflammatory drugs and their derivatives target gamma-secretase at a novel site. Evidence for an allosteric mechanism. J. Biol. Chem. 2004, 279:43419-43426.
48. Kukar T.L., et al. Substrate-targeting gamma-secretase modulators. Nature 2008, 453:925-929.
49. Okochi M., et al. Secretion of the Notch-1 Abeta-like peptide during Notch signaling. J. Biol. Chem. 2006, 281:7890-7898.
50. Sato T., et al. Signal peptide peptidase: biochemical properties and modulation by nonsteroidal antiinflammatory drugs. Biochemistry 2006, 45:8649-8656.
51. Iben L.G., et al. Signal peptide peptidase and gamma-secretase share equivalent inhibitor binding pharmacology. J. Biol. Chem. 2007, 282:36829-36836.
52. Weggen S., et al. Evidence that nonsteroidal anti-inflammatory drugs decrease amyloid beta 42 production by direct modulation of gamma-secretase activity. J. Biol. Chem. 2003, 278:31831-31837.
53. Czirr E., et al. Insensitivity to Abeta 42-lowering non-steroidal anti-inflammatory drugs (NSAIDs) and gamma-secretase inhibitors is common among aggressive presenilin-1 mutations. J. Biol. Chem. 2007, 282:24504-24513.
54. Beel A.J., et al. Nonspecificity of binding of gamma-secretase modulators to the amyloid precursor protein. Biochemistry 2009, 48:11837-11839.
55. Schneider P., Schneider G. Collection of bioactive reference compounds for focused library design. QSAR Comb. Sci. 2003, 22:713-718.
56. Labute P., et al. Flexible alignment of small molecules. J. Med. Chem. 2001, 44:1483-1490.
57. Tanrikulu Y., et al. Homology model adjustment and ligand screening with a pseudoreceptor of the human histamine H4 receptor. ChemMedChem 2009, 4:820-827.
58. Tanrikulu Y., Schneider G. Pseudoreceptor models in drug design: bridging ligand- and receptor-based virtual screening. Nat. Rev. Drug. Discov. 2008, 7:667-677.